These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3204005)

  • 1. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models.
    Gabizon A; Goren D; Barenholz Y
    Isr J Med Sci; 1988; 24(9-10):512-7. PubMed ID: 3204005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
    Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
    Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat.
    van Hoesel QG; Steerenberg PA; Crommelin DJ; van Dijk A; van Oort W; Klein S; Douze JM; de Wildt DJ; Hillen FC
    Cancer Res; 1984 Sep; 44(9):3698-705. PubMed ID: 6744286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW; Allen TM
    J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers.
    Gabizon A; Goren D; Fuks Z; Barenholz Y; Dagan A; Meshorer A
    Cancer Res; 1983 Oct; 43(10):4730-5. PubMed ID: 6883331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice.
    Mizuno Y; Naoi T; Nishikawa M; Rattanakiat S; Hamaguchi N; Hashida M; Takakura Y
    J Control Release; 2010 Jan; 141(2):252-9. PubMed ID: 19778560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antitumor activity of doxorubicin in the treatment of hemocytoblastosis La and various ascites tumors in mice].
    Ul'ianova LA; Tarasova VE; Bazhanov VS; Iudina OI; Gol'dberg LE
    Antibiotiki; 1984 Nov; 29(11):861-6. PubMed ID: 6524889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
    Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A
    Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity.
    Charrois GJ; Allen TM
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1058-67. PubMed ID: 12808004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes.
    Hosoda J; Unezaki S; Maruyama K; Tsuchiya S; Iwatsuru M
    Biol Pharm Bull; 1995 Sep; 18(9):1234-7. PubMed ID: 8845812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
    Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
    Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
    Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
    J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.